Login / Signup

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.

Martin H VossMichael S GordonMonica MitaBrian RiniVicky MakkerTeresa MacarullaDavid C SmithAndrés CervantesIgor PuzanovRoberto PiliDing WangShadia JalalShubham PantManish R PatelRachel L NeuwirthAaron EnkeYaping ShouFarhad SedaratiDouglas V FallerHoward A Burris
Published in: British journal of cancer (2020)
ClinicalTrials.gov, NCT01058707.
Keyphrases
  • open label
  • endometrial cancer
  • placebo controlled
  • double blind
  • randomized controlled trial
  • muscle invasive bladder cancer